Proton beam radiotherapy: report of the first patient treated at the Centro Nazionale di Adroterapia Oncologica (CNAO)

Roberto Orecchia1,2, Anurita Srivastava1, Maria Rosaria Fiore1, Viviana Vitolo1, Piero Fossati1,2, Barbara Vischioni1, Alberto Iannalfi1, Jeffrey Tuan1, Mario Ciocca1, Silvia Molinelli1, Alfredo Mirandola1, Gloria Vilches1, Andrea Mairani1, Barbara Tagaste1, Guido Baronii,3, Sandro Rossi1, and Marco Krengli1,4

1Fondazione CNAO, Pavia; 2European Institute of Oncology, Milan; 3Politecnico di Milano, Milan; 4University of Piemonte Orientale, Novara, Italy

ABSTRACT

Proton beam radiotherapy, an innovative treatment modality, allows delivery of high radiation doses to the target while sparing surrounding healthy structures. The Centro Nazionale di Adroterapia Oncologica (CNAO), equipped with a synchrotron and capable of using both protons and ions, initiated its clinical activity in September 2011. The first treatment of a skull base tumor with protons is reported here. The case of a 26-year-old man with an intracranial low-grade chondrosarcoma of the right petroclival junction is discussed with emphasis on technical and clinical details. Two previous surgical interventions had achieved partial removal of the tumor and the patient was treated with protons for residual disease. The prescribed dose was 70 GyE in 35 fractions of 2 GyE. Treatment was completed with minimal acute toxicity consisting of grade 1 alopecia and nausea. Nine months after treatment the disease is locally controlled. Use of high-energy protons at CNAO is a safe and effective means of treating a tumor located near critical normal structures.

Key words: proton therapy, chondrosarcoma, skull base, hadron therapy.

Disclosure: The authors have no conflict of interest.

Acknowledgments: The authors acknowledge the President, the Technical and Scientific Committee, the Advisory Board, the General Secretary, the Office of Communications, the Departments of Safety Prevention and Environment Service, of Legal Affairs and Human Resources, of Radioprotection, of the Accelerator, of Infrastructure, of Administration and Finance, the Office of Quality, the Radiation Technologist Unit and the Nursing Staff for their contribution that made possible the start of clinical activity at CNAO.

Correspondence to: Roberto Orecchia, Fondazione CNAO, Strada Privata Campeggi, 27100 Pavia, Italy. Tel +39-0382-078612; fax +39-0382-078903; email roberto.orecchia@cnao.it

Received December 3, 2012; accepted December 6, 2012.